Cargando…
Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog p...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680638/ https://www.ncbi.nlm.nih.gov/pubmed/23888252 http://dx.doi.org/10.1007/s13555-013-0019-9 |
_version_ | 1782273147438891008 |
---|---|
author | Cowey, C. Lance |
author_facet | Cowey, C. Lance |
author_sort | Cowey, C. Lance |
collection | PubMed |
description | Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog pathway plays an important role in the pathogenesis of this disease and can be exploited as a treatment target. Several agents that inhibit the Hedgehog pathway have reached clinical studies and one drug, vismodegib, has recently been US Food and Drug Administration (FDA) approved based on clinical activity and tolerability in patients with advanced basal-cell carcinoma. This review will describe the clinical development of vismodegib, as well as the proper application of the drug in clinical practice. Other important clinical questions, such as mechanisms of resistance to vismodegib and the role of other Hedgehog pathway inhibitors currently in development will also be discussed. |
format | Online Article Text |
id | pubmed-3680638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-36806382013-06-13 Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond Cowey, C. Lance Dermatol Ther (Heidelb) Review Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog pathway plays an important role in the pathogenesis of this disease and can be exploited as a treatment target. Several agents that inhibit the Hedgehog pathway have reached clinical studies and one drug, vismodegib, has recently been US Food and Drug Administration (FDA) approved based on clinical activity and tolerability in patients with advanced basal-cell carcinoma. This review will describe the clinical development of vismodegib, as well as the proper application of the drug in clinical practice. Other important clinical questions, such as mechanisms of resistance to vismodegib and the role of other Hedgehog pathway inhibitors currently in development will also be discussed. Springer Healthcare 2013-03-02 /pmc/articles/PMC3680638/ /pubmed/23888252 http://dx.doi.org/10.1007/s13555-013-0019-9 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Review Cowey, C. Lance Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond |
title | Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond |
title_full | Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond |
title_fullStr | Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond |
title_full_unstemmed | Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond |
title_short | Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond |
title_sort | targeted therapy for advanced basal-cell carcinoma: vismodegib and beyond |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680638/ https://www.ncbi.nlm.nih.gov/pubmed/23888252 http://dx.doi.org/10.1007/s13555-013-0019-9 |
work_keys_str_mv | AT coweyclance targetedtherapyforadvancedbasalcellcarcinomavismodegibandbeyond |